Teva’s shares climbed 21% to a high of $20.01 in early trading. They haven’t traded this high since late 2018. Sanofi’s American depositary receipts meanwhile rose 4.6% to $48.

On Saturday, Teva Pharmaceuticals Industries Ltd. TEVA and Sanofi SA SNY presented new, detailed results from the RELIEVE UCCD Phase 2b study of duvakitug (TEV’574/SAR447189) for moderate-to ...

Teva Pharmaceuticals’TEVA-2.59%decrease; red down pointing triangle shares soared and Sanofi’sSAN 0.05%increase; green up pointing triangle stock moved higher following positive results from ...

Teva and Sanofi are gathering data for the longer dosing interval. Participants who completed the 14-week Phase 2b test could continue receiving treatment in a long-term extension study lasting ...

With the new findings in hand, Sanofi and Teva are now plotting a phase 3 study for duvakitug, pending talks with regulators. Duvakitug hails from Teva’s labs, though Sanofi got in on the action ...

Sanofi and Teva plan to initiate Phase 3 development in IBD, pending regulatory discussions. PARSIPPANY, N.J. and PARIS, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, ...

Teva and Sanofi said last year they would collaborate on developing a treatment for inflammatory bowel disease (IBD), hoping it will become a blockbuster drug - or one that generates annual sales ...

Sanofi has acquired rights to co-develop and co-market Teva’s TEV-48574, currently in phase 2b testing for both ulcerative colitis and Crohn’s disease, with results expected next year.

Sanofi and Teva Pharmaceuticals have reported that the Phase IIb RELIEVE UCCD study of the human IgG1-λ2 monoclonal antibody targeting TL1A, duvakitug, met its primary endpoints in patients with ...

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Sanofi today announced an update to the timing ...